Hispanic Men Are More Likely To Suffer From Polyps in Colon Than Women.
Among Hispanics, men are twice as conceivable as women to have colon polyps and are also more disposed to to have multiple polyps, a unusual study in Puerto Rico has found. The researchers also found that the bone up patients older than 60 were 56 percent more likely to have polyps than those younger than 60. Polyps are growths in the gargantuan intestine. Some polyps may already be cancerous or can become cancerous.
The research included 647 patients aged 50 and older undergoing colorectal cancer screening at a gastroenterology clinic in Puerto Rico. In 70 percent of patients with polyps, the growths were on the rational subsidiary of the colon. In white patients, polyps are typically found on the left facet of the colon. This difference may result from underlying molecular differences in the two patient groups, said go into author Dr Marcia Cruz-Correa, an associate professor of medicine and biochemistry at the University of Puerto Rico Cancer Center.
The judgement about polyp location is important because it highlights the straits to use colonoscopy when conducting colorectal cancer screening in Hispanics. This is the most effective approach of detecting polyps on the right side of the colon. The study was to be presented Sunday at the Digestive Diseases Week gathering in New Orleans.
Friday 26 February 2016
Wednesday 24 February 2016
The Experimental Drug Against Lung Cancer Prolongs Patients' Lives
The Experimental Drug Against Lung Cancer Prolongs Patients' Lives.
Researchers gunfire they prolonged survival for some patients with advanced non-small cubicle lung cancer, for whom the median survival is currently only about six months. One on discovered that an experimental analgesic called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or unskilfully 40000 nation worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited ancient patients, who represent the majority of those with lung cancer worldwide. Roughly 100000 patients with lung cancer in the United States are over the maturity of 70. "This is our toughest cancer in many ways," said Dr Mark Kris, anchorwoman of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220000 Americans each year, and over a million commonalty worldwide. Sadly, it is our nation's - and our world's - greatest cancer".
The before all study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small stall lung cancer with a specific mutation of the ALK gene, which makes that gene amalgamate with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc. "The patients were treated for an standard of six months, and more than 90 percent saw their tumors contract in size and 72 percent of participants remained progression-free six months after treatment," said haunt author Dr Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to return to treatment.
About half of patients prepared nausea, vomiting and diarrhea but these airs effects eased over time. The fusion gene was first discovered to play a impersonation in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported pecuniary ties to Pfizer.
Researchers gunfire they prolonged survival for some patients with advanced non-small cubicle lung cancer, for whom the median survival is currently only about six months. One on discovered that an experimental analgesic called crizotinib shrank tumors in the majority of lung cancer patients with a specific gene variant. An estimated 5 percent of lung cancer patients, or unskilfully 40000 nation worldwide, have this gene variant.
A second study found that a double-chemotherapy regimen benefited ancient patients, who represent the majority of those with lung cancer worldwide. Roughly 100000 patients with lung cancer in the United States are over the maturity of 70. "This is our toughest cancer in many ways," said Dr Mark Kris, anchorwoman of a Saturday press conference at the annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago. "It affects 220000 Americans each year, and over a million commonalty worldwide. Sadly, it is our nation's - and our world's - greatest cancer".
The before all study, a phase 1 trial, found that 87 percent of 82 patients with advanced non-small stall lung cancer with a specific mutation of the ALK gene, which makes that gene amalgamate with another, responded robustly to treatment with crizotinib, which is made by Pfizer Inc. "The patients were treated for an standard of six months, and more than 90 percent saw their tumors contract in size and 72 percent of participants remained progression-free six months after treatment," said haunt author Dr Yung-Jue Bang, a professor in the department of internal medicine at Seoul National University College of Medicine in South Korea. Ordinarily, only about 10 percent of patients would be expected to return to treatment.
About half of patients prepared nausea, vomiting and diarrhea but these airs effects eased over time. The fusion gene was first discovered to play a impersonation in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported pecuniary ties to Pfizer.
Tuesday 16 February 2016
Gonorrhea Can Not Be Treated By Existing Antibiotics
Gonorrhea Can Not Be Treated By Existing Antibiotics.
The sexually transmitted condition gonorrhea is comely increasingly resistant to available antibiotics, including the latest oral antibiotic used to treat the bacterium, new Canadian research shows. In a investigate of nearly 300 people infected with Neisseria gonorrhoeae, the researchers found a treatment remissness rate of nearly 7 percent in people treated with cefixime, the last available oral antibiotic for gonorrhea. "Gonorrhea is a bacterium that's extraordinary in its ability to mutate quickly, and we no longer have the same over-sufficiency of options anymore," said study author Dr Vanessa Allen, a medical microbiologist with Public Health Ontario in Toronto.
So "We scarcity to start thinking about how we give antibiotics in see of a pipeline that's ending. I think gonorrhea will become a paradigm for drug resistance in general". Another accomplished agreed. "We've been lucky. For quite some time, we've had treatments for gonorrhea that are simple, inexpensively and effective, and a single dose," explained Dr Robert Kirkcaldy, a medical epidemiologist with the US Centers for Disease Control and Prevention, who wrote an article accompanying the study. "But now we're match out of treatment options, and there's a very real possibility that there will be untreatable gonorrhea in the future.
This is a dangerous public health crisis on the horizon". The CDC is so worried that the agency issued new treatment recommendations last August. The CDC advised doctors to stopping using cefixime to treat gonorrhea, and instead use the injectable antibiotic ceftriaxone. Ceftriaxone is in the same refinement of antibiotics as cefixime.
The CDC has also recommended that physicians closely monitor their patients to safeguard that the treatment is working, and to add a second class of antibiotics to treatment if they suspect the ceftriaxone injection hasn't knocked out the infection. Gonorrhea is an exceedingly common infection. More than 320000 cases were reported in the United States in 2011.
The sexually transmitted condition gonorrhea is comely increasingly resistant to available antibiotics, including the latest oral antibiotic used to treat the bacterium, new Canadian research shows. In a investigate of nearly 300 people infected with Neisseria gonorrhoeae, the researchers found a treatment remissness rate of nearly 7 percent in people treated with cefixime, the last available oral antibiotic for gonorrhea. "Gonorrhea is a bacterium that's extraordinary in its ability to mutate quickly, and we no longer have the same over-sufficiency of options anymore," said study author Dr Vanessa Allen, a medical microbiologist with Public Health Ontario in Toronto.
So "We scarcity to start thinking about how we give antibiotics in see of a pipeline that's ending. I think gonorrhea will become a paradigm for drug resistance in general". Another accomplished agreed. "We've been lucky. For quite some time, we've had treatments for gonorrhea that are simple, inexpensively and effective, and a single dose," explained Dr Robert Kirkcaldy, a medical epidemiologist with the US Centers for Disease Control and Prevention, who wrote an article accompanying the study. "But now we're match out of treatment options, and there's a very real possibility that there will be untreatable gonorrhea in the future.
This is a dangerous public health crisis on the horizon". The CDC is so worried that the agency issued new treatment recommendations last August. The CDC advised doctors to stopping using cefixime to treat gonorrhea, and instead use the injectable antibiotic ceftriaxone. Ceftriaxone is in the same refinement of antibiotics as cefixime.
The CDC has also recommended that physicians closely monitor their patients to safeguard that the treatment is working, and to add a second class of antibiotics to treatment if they suspect the ceftriaxone injection hasn't knocked out the infection. Gonorrhea is an exceedingly common infection. More than 320000 cases were reported in the United States in 2011.
Monday 15 February 2016
Experimental Diet Pill Contrave Brought A Small Weight Loss
Experimental Diet Pill Contrave Brought A Small Weight Loss.
Contrave, an theoretical bias loss drug that combines an antidepressant with an anti-addiction medication, appears to inform users shed pounds when taken along with a healthy diet and exercise, researchers report. People who took the stupefy for more than a year lost an average of 5 percent or more of body weight, depending on the quantity used, the team said. However, the regimen did come with side effects, and about half of scrutinize participants dropped out before completing a year of treatment.
Contrave is combination of two well-known drugs, naltrexone (Revia, in use to fight addictions) and the antidepressant bupropion (known by a number of names, including Wellbutrin). The drug, which is up for US Food and Drug Administration evaluate this December, appears to promote weight loss by changing the workings of the body's central nervous system, the researchers report.
The researchers, who divulge their findings online July 29, 2010 in The Lancet, enrolled men (15 percent) and women (85 percent) from around the country, ranging in length of existence from 18 to 65. They were all either heavy or overweight with high blood fat levels or merry blood pressure. The participants were told to eat less and exercise, and they were randomly assigned to wolf a twice-daily placebo or a combination of the two drugs with naltrexone at one of two levels.
Contrave, an theoretical bias loss drug that combines an antidepressant with an anti-addiction medication, appears to inform users shed pounds when taken along with a healthy diet and exercise, researchers report. People who took the stupefy for more than a year lost an average of 5 percent or more of body weight, depending on the quantity used, the team said. However, the regimen did come with side effects, and about half of scrutinize participants dropped out before completing a year of treatment.
Contrave is combination of two well-known drugs, naltrexone (Revia, in use to fight addictions) and the antidepressant bupropion (known by a number of names, including Wellbutrin). The drug, which is up for US Food and Drug Administration evaluate this December, appears to promote weight loss by changing the workings of the body's central nervous system, the researchers report.
The researchers, who divulge their findings online July 29, 2010 in The Lancet, enrolled men (15 percent) and women (85 percent) from around the country, ranging in length of existence from 18 to 65. They were all either heavy or overweight with high blood fat levels or merry blood pressure. The participants were told to eat less and exercise, and they were randomly assigned to wolf a twice-daily placebo or a combination of the two drugs with naltrexone at one of two levels.
Sunday 14 February 2016
New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used
New Non Invasive Test For Detection Of Tumors Of The Colon Is More Accurate Than Previously Used.
A fresh noninvasive assess to locate pre-cancerous polyps and colon tumors appears to be more accurate than tendency noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The quest for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research. In a precedence trial, the new examine was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.
Dr Floriano Marchetti, an aide-de-camp professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the brand-new evaluation could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings fundamental to be replicated on a larger scale. Hopefully, this is a good start for a more reliable test".
Dr Durado Brooks, chief of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more engaging if we ever get this kind of data in a screening population".
The study's lead researcher remained optimistic. "There are 150000 renewed cases of colon cancer each year in the United States, treated at an estimated fetch of $14 billion," noted Dr David A Ahlquist, professor of pharmaceutical and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The fancy is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a modus vivendi that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".
Ahlquist was scheduled to announce the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The recent technology, called the Cologuard sDNA test, mill by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.
If a DNA distortion is found, a colonoscopy would still be needed to confirm the results, just as happens now after a supportive fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's crew tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.
The assay was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this immensity are considered pre-cancers and most likely to progress to cancer.
A fresh noninvasive assess to locate pre-cancerous polyps and colon tumors appears to be more accurate than tendency noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say. The quest for a highly accurate, noninvasive alternative to invasive screens such as colonoscopy or sigmoidoscopy is a "Holy Grail" of colon cancer research. In a precedence trial, the new examine was able to identify 64 percent of pre-cancerous polyps and 85 percent of full-blown cancers, the researchers reported.
Dr Floriano Marchetti, an aide-de-camp professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the brand-new evaluation could be an important adjunct to colon cancer screening if it proves itself in further study. "Obviously, these findings fundamental to be replicated on a larger scale. Hopefully, this is a good start for a more reliable test".
Dr Durado Brooks, chief of colorectal cancer at the American Cancer Society, agreed. "These findings are interesting. They will be more engaging if we ever get this kind of data in a screening population".
The study's lead researcher remained optimistic. "There are 150000 renewed cases of colon cancer each year in the United States, treated at an estimated fetch of $14 billion," noted Dr David A Ahlquist, professor of pharmaceutical and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn. "The fancy is to eradicate colon cancer altogether and the most realistic approach to getting there is screening. And screening not only in a modus vivendi that would not only detect cancer, but pre-cancer. Our test takes us closer to that dream".
Ahlquist was scheduled to announce the findings of the study Thursday in Philadelphia at a meeting on colorectal cancer sponsored by the American Association for Cancer Research. The recent technology, called the Cologuard sDNA test, mill by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.
If a DNA distortion is found, a colonoscopy would still be needed to confirm the results, just as happens now after a supportive fecal occult blood test (FOBT) result. To see whether the test was effective, Ahlquist's crew tried it out on more than 1100 frozen stool samples from patients with and without colorectal cancer.
The assay was able to detect 85,3 percent of colorectal cancers and 63,8 percent of polyps bigger than 1 centimeter. Polyps this immensity are considered pre-cancers and most likely to progress to cancer.
Saturday 6 February 2016
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing bravery attacks, blood clots or obliteration than the yardstick lower dose in patients who had received artery-opening stents, renewed research shows. The higher dose - understudy the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to reply to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have dirty platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the supplemental study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to sanctum lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to review heart patients who don't respond well to Plavix? "It remains erratic to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an effective study to have done but the key issues are that a significant proportion of the patients remained with weighty platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the quantity was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a gamy reactivity standing is associated with poorer outcomes after angioplasty and/or stenting. But until now, a ret rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Higher doses of the blood-thinner Plavix were no better at preventing bravery attacks, blood clots or obliteration than the yardstick lower dose in patients who had received artery-opening stents, renewed research shows. The higher dose - understudy the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to reply to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have dirty platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the supplemental study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to sanctum lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to review heart patients who don't respond well to Plavix? "It remains erratic to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an effective study to have done but the key issues are that a significant proportion of the patients remained with weighty platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the quantity was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a gamy reactivity standing is associated with poorer outcomes after angioplasty and/or stenting. But until now, a ret rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Tuesday 2 February 2016
Many Women In The First Year After Menopause Deteriorating Memory And Fine Motor Skills
Many Women In The First Year After Menopause Deteriorating Memory And Fine Motor Skills.
Women effective through menopause from time to time sensation they are off their mental game, forgetting phone numbers and passwords, or struggling to find a particular word. It can be frustrating, puzzling and worrisome, but a small new study helps to explain the struggle. Researchers found that women in the word go year after menopause perform slightly worse on certain mentally ill tests than do those who are approaching their post-reproductive years. "This study shows, as have others, that there are cognitive crazy declines that are real, statistically significant and clinically significant," said study author Miriam Weber, an subordinate professor in the department of neurology at the University of Rochester in Rochester, NY "These are arcane declines in performance, so women aren't becoming globally impaired and unable to function. But you notification it on a daily basis".
The study is published in the current issue of the journal Menopause. According to the researchers, the system of learning, retaining and applying new information is associated with regions of the sagacity that are rich in estrogen receptors. The natural fluctuation of the hormone estrogen during menopause seems to be linked to problems associated with philosophy and memory. "We found the problem is not related to absolute hormone levels. Estrogen declines in the transition, but before it falls, there are sudden fluctuations".
Weber explained that it is the variation in estrogen up that most likely plays a critical role in creating the memory problems many women experience. As the body readjusts to the changes in hormonal levels eventually after a woman's period stops, the researchers be suspicious of mental challenges diminish. While Weber said it is important that women arrange that memory issues associated with menopause are most likely normal and temporary, the study did not include women whose periods had stopped for longer than one year. Weber added that she plans to pinpoint more carefully how long-term honour and thinking problems persist in a future study.
Other research has offered conflicting conclusions about the lunatic changes associated with menopause, the study authors wrote. The Chicago instal of the Study of Women's Health Across the Nation (SWAN) initially found no relation between what stage of menopause women were in and how they performed on tests of working celebration or perceptual speed. However, a different SWAN work identified deficits in memory and processing speed in the late menopausal stage.
Studies of menopause typically limit distinct stages of menopause, although researchers may differ in where they draw the line between those transitions. The researchers confusing with this study said that the variation in findings between studies may be due to different ways of staging menopause.
Women effective through menopause from time to time sensation they are off their mental game, forgetting phone numbers and passwords, or struggling to find a particular word. It can be frustrating, puzzling and worrisome, but a small new study helps to explain the struggle. Researchers found that women in the word go year after menopause perform slightly worse on certain mentally ill tests than do those who are approaching their post-reproductive years. "This study shows, as have others, that there are cognitive crazy declines that are real, statistically significant and clinically significant," said study author Miriam Weber, an subordinate professor in the department of neurology at the University of Rochester in Rochester, NY "These are arcane declines in performance, so women aren't becoming globally impaired and unable to function. But you notification it on a daily basis".
The study is published in the current issue of the journal Menopause. According to the researchers, the system of learning, retaining and applying new information is associated with regions of the sagacity that are rich in estrogen receptors. The natural fluctuation of the hormone estrogen during menopause seems to be linked to problems associated with philosophy and memory. "We found the problem is not related to absolute hormone levels. Estrogen declines in the transition, but before it falls, there are sudden fluctuations".
Weber explained that it is the variation in estrogen up that most likely plays a critical role in creating the memory problems many women experience. As the body readjusts to the changes in hormonal levels eventually after a woman's period stops, the researchers be suspicious of mental challenges diminish. While Weber said it is important that women arrange that memory issues associated with menopause are most likely normal and temporary, the study did not include women whose periods had stopped for longer than one year. Weber added that she plans to pinpoint more carefully how long-term honour and thinking problems persist in a future study.
Other research has offered conflicting conclusions about the lunatic changes associated with menopause, the study authors wrote. The Chicago instal of the Study of Women's Health Across the Nation (SWAN) initially found no relation between what stage of menopause women were in and how they performed on tests of working celebration or perceptual speed. However, a different SWAN work identified deficits in memory and processing speed in the late menopausal stage.
Studies of menopause typically limit distinct stages of menopause, although researchers may differ in where they draw the line between those transitions. The researchers confusing with this study said that the variation in findings between studies may be due to different ways of staging menopause.
Allergic To Penicillin May Not Apply To Related Antibiotics
Allergic To Penicillin May Not Apply To Related Antibiotics.
Most patients who have a representation of penicillin allergy can safely clear antibiotics called cephalosporins, researchers say. Cephalosporins - which are akin to penicillin in their structure, uses and effects - are the most generally prescribed class of antibiotics.
So "Almost all patients undergoing major surgery come by antibiotics to reduce the risk of infections. Many patients with a history of penicillin allergy don't get the cephalosporin because of a relevant to of possible drug reaction.
They might get a second-choice antibiotic that is not quite as effective," sanctum author Dr James T Li, of the Mayo Clinic in Rochester, Minn, said in a item release from the American Academy of Allergy, Asthma & Immunology. He and his colleagues conducted penicillin allergy derma tests on 178 patients who reported a history of strict allergic (anaphylactic) reaction to penicillin.
Most patients who have a representation of penicillin allergy can safely clear antibiotics called cephalosporins, researchers say. Cephalosporins - which are akin to penicillin in their structure, uses and effects - are the most generally prescribed class of antibiotics.
So "Almost all patients undergoing major surgery come by antibiotics to reduce the risk of infections. Many patients with a history of penicillin allergy don't get the cephalosporin because of a relevant to of possible drug reaction.
They might get a second-choice antibiotic that is not quite as effective," sanctum author Dr James T Li, of the Mayo Clinic in Rochester, Minn, said in a item release from the American Academy of Allergy, Asthma & Immunology. He and his colleagues conducted penicillin allergy derma tests on 178 patients who reported a history of strict allergic (anaphylactic) reaction to penicillin.
Subscribe to:
Posts (Atom)